Study shows that use of statins increases risk of developing diabetes by 46 percent

March 4, 2015

New research published in Diabetologia (the journal of the European Association for the Study of Diabetes) shows that use of statins is associated with a 46% increase in the risk of developing diabetes, even after adjustment for confounding factors. The study is by Professor Markku Laakso, Institute of Clinical Medicine, University of Eastern Finland and Kuopio University Hospital, Finland, and colleagues.

Previous studies have suggested an increased risk (of varying levels) of developing diabetes associated with statin use. However, these studies have had limitations: study populations have been selective especially in statin trials which have included participants at high risk of cardiovascular disease. Therefore, the risk of diabetes in clinical trials is likely to differ from that in the general population. Very often in previous studies the diagnosis of diabetes has been based on self-reported diabetes or fasting glucose measurement, leading to an underestimation of the actual numbers of incident diabetes cases.

In this new study, the authors investigated the effects of statin treatment on the risk of and deterioration of blood sugar control in 8,749 non-diabetic men in a 6-year follow-up of the population-based Metabolic Syndrome in Men (METSIM) study, based in Kuopio, Finland. The authors also investigated the mechanisms of statin-induced diabetes by evaluating changes in insulin resistance and insulin secretion.

The participants, aged 45-73 years, were followed up for 5.9 years. New diabetes was diagnosed in 625 men with either an oral glucose tolerance test (OGTT), an HbA1c level of 6.5% or higher, or anti-diabetic medication started during the follow-up. Insulin sensitivity and secretion were evaluated.

The researchers found that, after the results were adjusted for age, body mass index (BMI), waist circumference, physical activity, smoking, alcohol intake, family history of diabetes, and beta-blocker and diuretic treatment, patients treated with statins were 46% more likely to develop diabetes than those not treated with statins.

The risk was dose-dependent for simvastatin and atorvastatin. Statin treatment significantly increased 2-h glucose (2hPG) at follow-up, with a nominally significant increase in fasting glucose (FPG). Insulin sensitivity was decreased by 24% and insulin secretion by 12% in individuals on statin treatment.

Furthermore, decreases in insulin sensitivity and insulin secretion were dose-dependent for simvastatin and atorvastatin. And, after adjustment for all the confounders mentioned above, high-dose simvastatin was associated with a 44% increased risk of developing diabetes , while for low-dose simvastatin the increased risk was 28% and for high-dose atorvastatin the increased risk was 37%. Overall, 29% of participants were taking simvastatin, while 53% were taking atorvastatin.

The authors say "The association of statin use with increased risk of developing diabetes is most likely directly related to decreasing both and secretion."

Furthermore, they stress that while the size of the study makes their conclusions reliable, the study sample was Caucasian men, so the applicability to women or people of other ethnic origin cannot be confirmed without further research.

They conclude: "Statin therapy was associated with a 46% of type 2 diabetes after adjustment for confounding factors, suggesting a higher risk of in the general population than previously reported."

Explore further: Statin use is linked to increased risk of developing diabetes, warn researchers

Related Stories

Statin use is linked to increased risk of developing diabetes, warn researchers

May 23, 2013
Treatment with high potency statins (especially atorvastatin and simvastatin) may increase the risk of developing diabetes, suggests a paper published today in BMJ.

Initiating statins linked to increased risk of T2DM

June 17, 2013
(HealthDay)—Initiating statin therapy is associated with an increased risk of type 2 diabetes, which is not explained by differential survival, according to a study published in the May issue of Diabetes Care.

Low risk of statin-linked hepatic injury in liver disease

January 7, 2015
(HealthDay)—For patients with chronic liver disease, statin initiation is associated with low overall incidence of hospitalization due to severe hepatic injury, according to a study published in the January issue of the ...

Association of physical activity with diabetes is weakest among women at high genetic risk

September 29, 2014
New research published in Diabetologia (the journal of the European Association for the Study of Diabetes) suggests that the protective effect of physical activity against diabetes is weakest among those at high genetic risk. ...

A simple method to monitor beta-cell death in individuals at-risk for type 1 diabetes

February 2, 2015
Type 1 diabetes is characterized by death and reduced function of β cells, which produce insulin. The presence of specific autoantibodies can identify individuals at risk of developing type 1 diabetes, and many of these ...

Intensive-dose statin therapy associated with increased risk of diabetes

June 21, 2011
An analysis of data from previously published studies indicates that intensive-dose statin therapy is associated with an increased risk of new-onset diabetes compared with moderate-dose therapy, according to a study in the ...

Recommended for you

Insulin pill may delay type 1 diabetes in some

November 21, 2017
(HealthDay)—It's often said that timing is everything. New research suggests this may be true when giving an insulin pill to try to prevent or delay type 1 diabetes.

Controlling diabetes with your phone might be possible someday

November 21, 2017
Think about this. You have diabetes, are trying to control your insulin levels and instead of taking a pill or giving yourself an injection, you click an app on your phone that tells your pancreas to bring blood sugar levels ...

Simple test predicts diabetes remission following weight loss surgery

November 21, 2017
A new simple test that helps predicts which people with type 2 diabetes will benefit most from weight loss surgery has been developed by a UCL-led team.

Pre-diabetes discovery marks step towards precision medicine

November 20, 2017
Researchers from the University of Sydney's Charles Perkins Centre have identified three specific molecules that accurately indicate insulin resistance, or pre-diabetes - a major predictor of metabolic syndrome, the collection ...

Scientists reverse diabetes in a mouse model using modified blood stem cells

November 15, 2017
Researchers at Boston Children's Hospital have successfully reversed type 1 diabetes in a mouse model by infusing blood stem cells pre-treated to produce more of a protein called PD-L1, which is deficient in mice (and people) ...

Pregnancy-related conditions taken together leave moms—and dads—at risk

November 14, 2017
Research has already shown that women who develop either diabetes or high blood pressure during pregnancy are at risk of getting type 2 diabetes, high blood pressure or heart disease years later. Now, a new study from a team ...

2 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

mbee1
not rated yet Mar 04, 2015
Before jumping on the bandwagon I suggest reading the trial and deciding for yourself whether the adjustments they make are correct. People on statins are overweight , usually do not exercise in any manner and are already on the road to being diabetic long before statins showed up. An article on this same page indicates an ignored glucose value correlates with risk of type 2 diabetes and this study did not adjust for that.
PeterElias
not rated yet Mar 05, 2015
This article commits one of the serious and easily preventable sins of medical reporting: it reports only RELATIVE risk, not absolute risk or natural numbers at risk. By doing so, it dramatically inflates the appearance of risk and misleads its reading public.

Using only the numbers in this article, 625 new diabetics in 8749 patients followed during the study, with a 46% difference between the statin and non-statin groups, means that 370 statin-treated patients developed new diabetes and 254 non-statin-treated patients developed diabetes.

This means that 116 more patients developed diabetes in the ~ 4374 patients treated with statins than one would have expected, based on the frequency in the non-statin-treated group. This is the absolute risk: 116/4374. In other words, 2.7 additional patients in every group of 100 patients similar to the study group will develop diabetes. This is an absolute risk of 2.7%, much different in impact than the reported 46% relative risk.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.